NCT07295665Not yet recruiting
External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
Thrombosis formation is the core mechanism for the occurrence of major adverse cardiovascular and cerebrovascular events in patients with coronary heart disease. Antithrombotic therapy is one of the most important treatment methods for secondary prevention of coronary heart disease. Antithrombotic drugs, while reducing ischemic events, often significantly increase the risk of bleeding. How to balance the risk of recurrent ischemic events and bleeding events in patients with coronary heart disease is a major challenge in the treatment of coronary heart disease. This project establishes a high-quality multicenter, prospective coronary heart disease cohort, with patients covering various clinical characteristics such as different regions, ages, and comorbidities. It verifies the ischemic risk and bleeding risk model developed in Project 1, compares the efficacy improvement of the new model with the traditional risk model, and verifies the effectiveness and stability of the model in different subgroups of the population, and assesses the generalizability of the model in real-world clinical practice, providing high-quality evidence-based basis for the formulation of individualized and precise antithrombotic strategies for coronary heart disease.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 3 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Jul 2029
- Lead sponsor
- Beijing Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07295665
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 1 Jan 2026 to the primary completion date, 31 Jul 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Combination of severe non-cardiovascular diseases: Expected lifespan does not exceed 6 months, such as patients with advanced cancer or other terminal diseases;
- Unable to cooperate with long-term follow-up: Such as patients with severe cognitive impairment or severe mental illness;
Other
- Non-cardiovascular death within 24 hours after admission.
Who the study is looking for
- Age ≥ 18 years old;
- Patients with clinically diagnosed various types of coronary heart disease, who are scheduled to receive long-term antithrombotic treatment;
- Patients with acute coronary syndrome or those who have undergone coronary intervention therapy, whose condition must be stable after treatment and meet the discharge criterias;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.